DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: NDI-034858 study drug
Other: Placebo

First Posted Date: 2021-08-11

Last Posted Date: 2023-09-28

Lead Sponsor: Takeda

Target Recruit Count: 259

Registration Number: NCT04999839

Locations: 🇺🇸
Nimbus site 139, Miami Lakes, Florida, United States
🇺🇸
Nimbus site 150, Macon, Georgia, United States
🇺🇸
Nimbus site 123, Skokie, Illinois, United States

and more 66 locations

A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin

Completed

Conditions: Hodgkin Disease
Lymphoma, T-Cell, Cutaneous

Interventions: Other: No Intervention

First Posted Date: 2021-08-10

Last Posted Date: 2024-07-08

Lead Sponsor: Takeda

Target Recruit Count: 51

Registration Number: NCT04998331

Locations: 🇪🇸
Hospital Universitario de Alava, Vitoria-Gasteiz, Araba, Spain
🇪🇸
Hospital Universitario Donostia, Donostia, Gipuzkoa, Spain
🇪🇸
Hospital Universitario Son Espases, Palma de Mallorca, Mallorca, Spain

and more 27 locations

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-935 Oral Tablet
Drug: [14C]TAK-935 IV Infusion
Drug: [14C]TAK-935 Oral Solution

First Posted Date: 2021-08-05

Last Posted Date: 2021-10-04

Lead Sponsor: Takeda

Target Recruit Count: 6

Registration Number: NCT04992442

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland

Completed

Conditions: Inflammatory Bowel Diseases
Crohns Disease
Colitis, Ulcerative

First Posted Date: 2021-08-04

Last Posted Date: 2024-07-19

Lead Sponsor: Takeda

Target Recruit Count: 92

Registration Number: NCT04989907

Locations: 🇨🇭
Clarunis AG, Basel, Switzerland
🇨🇭
Bauchzentrum INSELSPITAL, Universitatsspital Bern, Bern, Switzerland
🇨🇭
Gastroenterologische Praxis Balsiger, Seibold & Partner Crohn-Colitis-Zentrum, Bern, Switzerland

and more 3 locations

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Phase 2

Withdrawn

Conditions: Myelodysplastic Syndromes (MDS)

Interventions: Drug: Pevonedistat
Drug: Decitabine
Drug: Cedazuridine

First Posted Date: 2021-08-02

Last Posted Date: 2021-09-29

Lead Sponsor: Takeda

Registration Number: NCT04985656

A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency

Phase 1

Completed

Conditions: Congenital Protein C Deficiency

Interventions: Drug: TAK-662

First Posted Date: 2021-08-02

Last Posted Date: 2025-05-07

Lead Sponsor: Takeda

Target Recruit Count: 5

Registration Number: NCT04984889

Locations: 🇯🇵
Chiba Children's Hospital, Chiba, Japan
🇯🇵
Nara Medical University Hospital, Kashihara, Nara, Japan
🇯🇵
Chiba University Hospital, Chiba, Japan

and more 1 locations

A Study of Real Life Treatment for Multiple Myeloma (MM)

Active, not recruiting

Conditions: Multiple Myeloma

First Posted Date: 2021-08-02

Last Posted Date: 2025-04-04

Lead Sponsor: Takeda

Target Recruit Count: 357

Registration Number: NCT04985643

Locations: 🇷🇺
Kirov Research Institute of Hematology and Blood Transfusion, Kirov, Kirov Region, Russian Federation
🇷🇺
Orenburgskaya Regional Clinical Hospital n.a. V.I. Voinova, Orenburg, Orenburgskaya District, Russian Federation
🇷🇺
Razumovskiy Saratov State Medical University, University Clinical, Saratov, Saratov Region, Russian Federation

and more 21 locations

A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Alogliptin Benzoate

First Posted Date: 2021-07-28

Last Posted Date: 2022-04-05

Lead Sponsor: Takeda

Target Recruit Count: 3623

Registration Number: NCT04980040

A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: NesinaAct® Tablet

First Posted Date: 2021-07-28

Last Posted Date: 2022-03-07

Lead Sponsor: Takeda

Target Recruit Count: 730

Registration Number: NCT04980014

A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

Phase 3

Completed

Conditions: Fabry Disease

Interventions: Biological: REPLAGAL

First Posted Date: 2021-07-23

Last Posted Date: 2024-10-07

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT04974749

Locations: 🇨🇳
Xiangya Hospital, Central South University, Changsha, China
🇨🇳
The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
🇨🇳
Shandong Provincial Hospital, Jinan, China

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy